Brokerages Set Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Price Target at $28.50

Posted by Brian Himes on Aug 31st, 2026

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) has been given an average recommendation of “Moderate Buy” by the nine analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $28.50.

A number of analysts recently commented on GLUE shares. Wedbush dropped their price objective on Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday, August 3rd. Wells Fargo & Company reduced their target price on shares of Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Zacks Research raised shares of Monte Rosa Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. JPMorgan Chase & Co. lowered their price target on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Finally, Guggenheim reissued a “buy” rating and issued a $28.00 price objective on shares of Monte Rosa Therapeutics in a research report on Tuesday, August 25th.

Check Out Our Latest Report on GLUE

Insider Activity

In other Monte Rosa Therapeutics news, Director Anthony M. Manning sold 10,000 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $23.11, for a total transaction of $231,100.00. Following the transaction, the director owned 10,000 shares of the company’s stock, valued at $231,100. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Sharon Townson sold 6,000 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $23.31, for a total value of $139,860.00. Following the transaction, the insider directly owned 67,845 shares in the company, valued at approximately $1,581,466.95. This represents a 8.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 79,603 shares of company stock worth $1,725,081 in the last three months. 6.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Several institutional investors have recently added to or reduced their stakes in GLUE. Allworth Financial LP acquired a new stake in Monte Rosa Therapeutics in the 2nd quarter worth about $30,000. Russell Investments Group Ltd. purchased a new stake in Monte Rosa Therapeutics in the 3rd quarter valued at about $32,000. Lazard Asset Management LLC increased its stake in shares of Monte Rosa Therapeutics by 42.9% during the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after acquiring an additional 3,262 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Monte Rosa Therapeutics by 32.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after acquiring an additional 776 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new position in shares of Monte Rosa Therapeutics during the 2nd quarter worth about $54,000. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Stock Performance

GLUE stock opened at $13.38 on Monday. Monte Rosa Therapeutics has a 1 year low of $4.60 and a 1 year high of $25.77. The stock’s 50 day moving average price is $19.72 and its 200 day moving average price is $18.63. The firm has a market cap of $1.14 billion, a P/E ratio of -7.60 and a beta of 1.59.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%.The company had revenue of $8.97 million for the quarter, compared to analysts’ expectations of $12.91 million. On average, research analysts predict that Monte Rosa Therapeutics will post -1.32 earnings per share for the current year.

Monte Rosa Therapeutics Company Profile

(Get Free Report)

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.